Updated: 2/19/2019

Scleroderma

Topic
Review Topic
0
0
https://upload.orthobullets.com/topic/322121/images/scleroderma1.jpg
https://upload.orthobullets.com/topic/322121/images/scleroderma2.jpg
https://upload.orthobullets.com/topic/322121/images/scleroderma3.jpg
https://upload.orthobullets.com/topic/322121/images/scleroderma4.jpg
https://upload.orthobullets.com/topic/322121/images/scleroderma_angio.jpg
Introduction
  • Overview
    • scleroderma is an autoimmune skin disease characterized by progressive hardening and induration of the skin and/or other structures (such as the subcutaneous tissues, muscles, and internal organs)
  • Epidemiology
    • demographics
      • females > males (3-14:1)
      • African Americans > Caucasians
      • 30-50 years old but can affect all ages
    • risk factors
      • genetic predisposition
      • exposure to potential triggers
        • silica, solvents (such as benzene), radiation
  • Pathophysiology
    • etiology
      • multifactorial
        • includes genetic predisposition and environmental triggers
    • pathophysiology
      • triad
        • collagen deposition with fibrosis
          • excessive deposition of collagen and other elements of the extracellular matrix in skin and internal organs
        • noninflammatory vasculopathy
          • due to fibroproliferation of microvasculature
        • autoimmunity
          • chronic inflammation with alterations of humoral and cellular immunity
          • increased release of inflammatory cells help initiate and propagate the fibrotic process
  • Genetics
    • inheritance pattern
      • usually sporadic
    • mutations
      • HLA
      • STAT4
        • associated with limited scleroderma
      • IRF5
        • associated with diffuse scleroderma
  • Associated conditions
    • other autoimmune diseases
    • esophageal dysmotility
      • atrophy of smooth muscles in esophagus can cause decreased lower esophageal sphincter pressure and dysmotility, leading to increased dysphagia and acid reflux
  • Prognosis
    • diffuse scleroderma is rapidly progressive
      • pulmonary, renal, or cardiac involvement indicates a more severe prognosis
      • has one of the highest mortalities among systemic autoimmune diseases
Classification
  • Based on extent of involvement
    • limited
      • limited involvement of the skin (mostly affects face and hands)
      • subtype is CREST syndrome
        • Calcinosis cutis/anti-Centromere antibody
        • Raynaud phenomenom
        • Esophageal dysmotility
        • Sclerodactyly
        • Telangiectasia
    • diffuse
      • widespread involvement of the skin
      • affects internal organs (kidneys, lungs, heart)
      • rapidly progressive
Presentation
  • Symptoms
    • skin
      • diffuse pruritus
      • Raynaud phenomenon  
        • decreased blood flow to skin due to vasospams from either cold temperatures or stress
        • color of affected area, commonly the digits, change from white (ischemia) to blue (hypoxia) to red (reperfusion)
    • musculoskeletal
      • mylagias
      • arthralgias
    • gastrointestinal
      • acid reflux 
    • respiratory
      • progressive dyspnea
      • dry cough due to restrictive lung disease
    • cardiac
      • palpitations or irregular heart beats
    • renal
      • hypertension
  • Physical exam
    • skin
      • tightness, induration, and hardening
        • affecting the fingers (sclerodactyly)
        • shiny with loss of “wrinkles” from skin folds
        • limited mobility due to skin tightening
          • PIP flexion contractures with compensatory MCP hyperextension
          • 1st webspace adduction contractures
      • digital ulceration
      • edema not responsive to diuresis
      • hyper- and hypopigmentation
      • telangiectasias on skin and mucosa
      • intracutaneous or subcutaneous calcinosis
    • respiratory
      • dry rales if there is pulmonary involvement
    • cardiac
      • symptoms of cor pulmonale if there is pulmonary involvement
        • jugular venous distention
        • edema
        • hepatomegaly
Imaging
  • CT
    • indications
      • to evaluate pulmonary involvement
    • findings
      • ground-glass appearance may indicate early lung fibrosis
      • honeycombing and bronchiolectasis indicate developed interstitial fibrosis
  • Angiography
    • findings
      • loss of flow to the digits
Studies
  • Labs
    • anti-centromere antibody
      • associated with limited scleroderma (CREST syndrome)
      • seen in ~50% of patients
    • anti-Scl-70 (anti-DNA topoisomerase I) antibody
      • associated with systemic scleroderma
      • seen in ~30% of patients
    • anti-nuclear antibody
      • seen in ~90-95% of affected patients
      • speckled or centromere pattern
      • nucleolar pattern is specific for systemic sclerosis
    • anti-histone antibody
      • also seen in drug-induced lupus, SLE, and RA
    • elevated inflammatory markers (ESR, CRP)
    • serum creatinine
      • to monitor for renal involvement
    • CXCL4
      • increase may indicate pulmonary fibrosis
    • N-terminal probrain natriuretic peptide
      • increase may indicate early pulmonary hypertension
  • Manometry
    • findings
      • aperistalsis in distal esophagus and decreased lower esophageal sphincter tone
  • Pulmonary function tests
    • used to detect early signs of pulmonary fibrosis
  • EKG
    • perform routine EKG to assess for cardiac involvement
Differential
  • Nephrogenic systemic fibrosis
  • Eosinophilic fasciitis
  • Graft-versus-host disease
Treatment
  • Nonoperative
    • immunosuppressive therapies
      • indications
        • to prevent progression of sclerosis, especially if the pulmonary system is involved
      • drugs
        • methotrexate
        • mycophenolate mofetil
        • cyclophosphamide
          • reserved for disease refractory to either methotrexate or mycophenolate mofetil
    • angiotensin-converting enzyme (ACE) inhibitor
      • indications
        • renal involvement of systemic sclerosis
    • anti-histamines
      • indications
        • pruritus
    • calcium-channel blockers
      • indications
        • Raynaud phenomenon
    • ambrisentan (endothelin receptor antagonist) and tadalafil (phosphodiesterase type 5 inhibitor) combination therapy
      • indications
        • pulmonary hypertension
  • Operative
    • I&D
      • indications
        • symptomatic calcinosis
    • PIP joint arthrodesis
      • indications
        • fixed PIP joint flexion deformity
    • MCP joint resection arthroplasty
      • indications
        • fixed MCP joint hyperextension deformity
    • adductor pollicis release +/- trapeziectomy
      • indications
        • 1st webspace contracture
    • amputation
      • indications
        • digital gangrene
Complications
  • Digital infarct/gangrene
  • Pulmonary hypertension
  • Pulmonary fibrosis
  • Renal failure
 

Please rate topic.

Average 0.0 of 0 Ratings

Thank you for rating! Please vote below and help us build the most advanced adaptive learning platform in medicine

The complexity of this topic is appropriate for?
How important is this topic for board examinations?
How important is this topic for clinical practice?
Topic COMMENTS (0)
Private Note